兄弟科技(002562.SZ):富馬酸比索洛爾片獲批上市
格隆匯1月16日丨兄弟科技(002562.SZ)公佈,公司全資子公司浙江兄弟藥業有限公司(簡稱“兄弟藥業”)於近日收到國家藥品監督管理局核准簽發的《藥品註冊證書》(證書編號:2024S00021、2024S00022)。
富馬酸比索洛爾片是選擇性β受體阻滯劑,用於治療高血壓、冠心病(心絞痛)、伴有心室收縮功能減退的中度至重度慢性穩定性心力衰竭。
富馬酸比索洛爾片由德國默克開發,1986年首先在德國上市銷售,1998年在中國上市銷售。目前國內獲得該藥品註冊證書的生產廠家主要有德國默克公司、成都苑東生物製藥股份有限公司、北京華素製藥股份有限公司、岳陽新華達製藥有限公司等。根據米內網數據統計,富馬酸比索洛爾片2022年國內市場銷售金額約人民幣14億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.